Type 2 Diabetes Mellitus Completed Phase Trials for Rosiglitazone (DB00412)

Also known as: Diabetes Mellitus Non-insulin-dependent / Type-2 Diabetes Mellitus / Diabetes Mellitus Type 2 (T2DM) / Diabetes Mellitus Type-2 / Type 2 Diabetes (T2DM) / Diabetes, Type 2 / Diabetes Mellitus, Type 2 (T2DM) / Diabetes Mellitus´╝îType 2 / Diabetes Type II / Type-II Diabetes Mellitus / Diabetes Mellitus 2 Type / T2DM / Diabetes Mellitus Type II / Type II Diabetes / Diabetes Mellitus, Type 2 / Type 2 Diabetes Mellitus (T2DM) / Diabetes Type Two / Diabetes Mellitus - Type 2 / Diabetes, Type II / Non-Insulin-Dependent Diabetes Mellitus / Diabetes Mellitus. Type 2 / Diabetes Type 2 / Type 2 Diabetes Mellitus (T2D) / Type 2 Diabetes (T2D) / Type II; Diabetes / Type II Diabetes Mellitus / Diabetes Mellitus, Type II / NIDDM / Type-2 Diabetes / Type 2 Diabetes Mellitus(T2DM) / Type 2 Diabetes / Type 2-diabetes / Noninsulin Dependent Diabetes Mellitus, Type II / Diabetes Mellitus Type 2 / Type Two Diabetes Mellitus / T2DM (Type 2 Diabetes Mellitus) / Type-2-diabetes Mellitus / Diabetes mellitus -adult onset / Diabetes mellitus non insulin-dep / Maturity onset diabetes / Diabetes mellitus maturity onset

IndicationStatusPhase
DBCOND0029752 (Type 2 Diabetes Mellitus)CompletedNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00324675Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic NephropathyTreatment
NCT00549874Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 DiabetesTreatment
NCT00636766Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque
NCT00194896Preferred Treatment of Type 1.5 DiabetesTreatment
NCT00256646Markers and Mechanisms of Vascular Disease in Type II Diabetes
NCT00413335Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in YouthPrevention
NCT00486187Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL StudyTreatment
NCT02456428Incretin-based Drugs and the Risk of Heart Failure
NCT01332370Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone
NCT00995995Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UK
NCT02475499Incretin-based Drugs and Pancreatic Cancer
NCT02476760Incretin-based Drugs and Acute Pancreatitis
NCT00577590Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DMTreatment